Browse by author
Lookup NU author(s): Professor Jelena Mann, Professor Fiona OakleyORCiD, Dr Ahmed Elsharkawy, Professor Derek Mann
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Myofibroblasts are critical cellular elements of wound healing generated at sites of injury by transdifferentiation of resident cells. A paradigm for this process is conversion of hepatic stellate cells (HSC) into hepatic myofibroblasts. Treatment of HSC with DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-azadC) blocked transdifferentiation. 5-azadC also prevented loss of IkappaBalpha and PPARgamma expression that occurs during transdifferentiation to allow acquisition of proinflammatory and profibrogenic characteristics. ChIP analysis revealed IkappaBalpha promoter is associated with transcriptionally repressed chromatin that converts to an active state with 5-azadC treatment. The methyl-CpG-binding protein MeCP2 which promotes repressed chromatin structure is selectively detected in myofibroblasts of diseased liver. siRNA knockdown of MeCP2 elevated IkappaBalpha promoter activity, mRNA and protein expression in myofibroblasts. MeCP2 interacts with IkappaBalpha promoter via a methyl-CpG-dependent mechanism and recruitment into a CBF1 corepression complex. We conclude that MeCP2 and DNA methylation exert epigenetic control over hepatic wound healing and fibrogenesisCell Death and Differentiation advance online publication, 9 June 2006; doi:10.1038/sj.cdd.4401979.
Author(s): Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA
Publication type: Article
Publication status: Published
Journal: Cell Death and Differentiation
Year: 2007
Volume: 14
Issue: 2
Pages: 275-285
ISSN (print): 1350-9047
ISSN (electronic): 1476-5403
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/sj.cdd.4401979
DOI: 10.1038/sj.cdd.4401979
Altmetrics provided by Altmetric
